40 results about "Multi epitope" patented technology

A polyclonal antibody composition specifically binds the pTonB epitope (SEQ ID NO: 11) from Acinetobacter baumannii and is elicited by immunization with a multi-epitope antigen comprising thioredoxin leader, rigid linker, and kernels including SEQ ID NOs: 6, 7, 11, 12, and 8. These antibodies enhance opsonophagocytic killing of A. baumannii Ci79 via classical complement activation and Fey receptor-mediated phagocytosis by bone marrow-derived macrophages. Absorption of pTonB-specific antibodies reduces killing by >70%, confirming epitope dominance. Passive transfer of the composition protects >60% of mice in a lethal intranasal challenge model. Pharmaceutical compositions, treatment methods (alone or with antibiotics like colistin), prophylactic uses, diagnostic kits, and polyclonal compositions are disclosed for combating multidrug-resistant A. baumannii infections.

The application discloses a porcine rotavirus VP7 protein conserved dominant B cell antigen epitope peptide or a combination thereof or a nucleic acid molecule and application, and further discloses a porcine rotavirus VP7 protein polyepitope fusion protein and a preparation method and application thereof.The polyepitope fusion protein can not only induce high-level specific antibody response and cellular immune response to the VP7 protein, effectively inhibit porcine rotavirus infection, but also has high safety and stability.Compared with a traditional fusion protein, the polyepitope fusion protein has significant advantages in production cost and immunization efficacy, and provides a feasible porcine rotavirus prevention and control scheme for the pig industry.

The present invention relates to a multi-epitope antigen comprising 20 epitope masses of from 20 to 36 amino acids, from a protein selected from the group consisting of NanA, PcsB, PhtD, Ply, PncO, StkP, PspA-F1 and PspA-F2. In addition, the invention relates to an immunogenic composition comprising said antigen and a pharmaceutically acceptable vehicle and / or adjuvant. In addition, the invention also discloses a pneumococcus diagnostic kit, which comprises the antigen combined with a detectable fraction or a bioactive fragment thereof; an antibody generated from the antigen; and instructions for use. Furthermore, the invention relates to the use of said antigens for the preparation of vaccines for the prevention of diseases caused by pneumococcal bacteria and for the production of monoclonal and polyclonal antibodies. Finally, the present invention relates to an in vitro diagnostic method of pneumococci comprising contacting said antigen bound to a detectable fraction or a biologically active fragment thereof with a sample of bodily fluids selected from mucus and urine expelled from blood, lower respiratory tract.

This invention relates to the application of the avian adenovirus serotype 4 multi-epitope recombinant chimeric protein rcF2 in the preparation of a kit for detecting avian adenovirus serotype 4 antibodies. The amino acid sequence of the avian adenovirus serotype 4 multi-epitope recombinant chimeric protein rcF2 is shown in SEQ ID NO.1. This invention utilizes the multi-epitope recombinant chimeric protein rcF2 to establish an indirect ELISA detection method and kit for detecting avian adenovirus serotype 4. This recombinant chimeric protein can be recognized by avian adenovirus serotype 4 positive sera, and the detection sensitivity of positive sera samples can reach 1:16000. It shows no cross-reactivity with antibodies against other pathogens, indicating that the ELISA detection method based on this multi-epitope recombinant chimeric protein rcF2 is simple to operate, enhances detection sensitivity, and has good specificity and repeatability.

The application discloses a SARS-CoV-2 epitope type vaccine multi-epitope combination and application, and belongs to the technical field of coronavirus vaccine research and development.The first aspect of the application relates to a fusion protein, which comprises in sequence: (a) a SARS-CoV-2 spike protein receptor binding domain or a functional fragment thereof; (b) a T cell epitope domain, comprising: a CTL epitope cluster, the CTL epitope cluster comprising at least one CD8+ T cell epitope polypeptide selected from SEQ ID NO: 1-15; and (c) an immunoglobulin Fc domain.The application adopts a tandem strategy of immunodominant epitopes + conserved epitopes, predicts high-affinity T cell epitopes by computational biology methods, evaluates the HLA restriction in different populations, introduces a flexible linker peptide for optimization design, evaluates the immune effect difference of different combinations through in vitro and animal models, analyzes the synergistic or competitive relationship between epitopes, and optimizes the vaccine design.Through systematic comparison of the immunological effect difference of different epitope combinations and the adaptability to various vaccine platforms, the application establishes an optimized safe, efficient, broad-spectrum and long-acting multi-epitope vaccine design strategy, and has significant application value and important transformation value.

The invention belongs to the technical field of genetic engineering, and particularly relates to a bovine group A rotavirus multi-epitope fusion protein and application thereof. The invention provides a bovine group A rotavirus multi-epitope peptide based on a ferritin nano-carrier, a fusion protein and application of the bovine group A rotavirus multi-epitope peptide and the fusion protein. The multi-epitope peptide disclosed by the invention is a multi-epitope fusion antigen which is formed by splicing cytotoxic T lymphocyte epitopes, helper T cell epitopes and B cell epitopes with high conservative property and strong immunogenicity and is formed by screening and obtaining the cytotoxic T lymphocyte epitopes, helper T cell epitopes and B cell epitopes with high conservative property and strong immunogenicity on the basis of VP4 and VP7 protein sequences of bovine group A rotaviruses by utilizing an immunoinformatics technology. Immunological evaluation shows that the monoclonal antibody has good antigen specificity and neutralizing activity. Animal experiment results show that the epitope peptide and the fusion protein can induce an organism to generate high-level neutralizing antibodies aiming at BRVA G6, G8, G10 and other multi-genotype strains, and the broad spectrum and durability of immune protection are remarkably improved.

Fusion proteins that include a backbone protein and at least one heterologous epitope from enterotoxigenic E. coli are provided. In some aspects, the fusion proteins are multiepitope fusion antigen proteins that include an LT B domain. In some aspects, the LT B domain is directly fused to an LT A domain (for example, the LT B domain does not include a starting methionine or signal sequence). In other aspects, the LT B domain includes a starting methionine and signal sequence. Methods of inducing an immune response in pigs utilizing the fusion proteins, such as an immune response that is protective against porcine post-weaning diarrhea, are also provided.

The present application relates to the technical field of vaccine preparation, and discloses a recombinant herpes zoster vaccine composition based on a multi-epitope chimeric antigen and a nano adjuvant, which comprises the following components in parts by weight: 1-3 parts of a multi-epitope chimeric antigen; 2-5 parts of a nano adjuvant; 0.5-1.5 parts of chitosan or trehalose; and 0.1-0.5 parts of other auxiliary materials, wherein the multi-epitope chimeric antigen comprises multiple immune epitopes of varicella zoster virus and is used for activating T cell and B cell immune responses, and the nano adjuvant comprises: 1-3 parts of a metal organic framework material and 1-3 parts of a carbon nanotube; the metal organic framework is an MIL-88B structure based on iron ions; and the carbon nanotube is functionally modified through acid pickling and ultraviolet light irradiation. The present application realizes the synergistic effect of antigen conformation maintenance, uniform compounding and stable reconstitution by constructing a nano composite structure and introducing a stabilizer and a microwave freeze-drying process.

The application discloses a bovine parainfluenza virus 3A and 3C type polyepitope antigen peptide, a complex thereof and application. The polyepitope antigen peptides BPMEV-3A and BPMEV-3C have amino acid sequences as shown in SEQ ID NO:1 and SEQ ID NO:3 respectively, and are connected by screening CTL epitopes, HTL epitopes and B cell epitopes from HN and F proteins of BPIV-3A and BPIV-3C strains. Animal immunization tests show that the antigen peptide and the complex thereof can effectively stimulate the body to produce specific IgG antibodies and neutralizing antibodies, induce Th1 type cellular immune response, and effectively eliminate viruses and reduce lung tissue lesions, and show good immunogenicity and protection effect. The application provides an efficient and safe vaccine candidate for prevention and control of BPIV-3, and has a good application prospect.

The invention discloses a recombinant bacillus calmette-guerin vaccine for expressing O and A type multi-epitope fusion peptides of foot and mouth disease viruses and application of the recombinant bacillus calmette-guerin vaccine, and belongs to the field of biotechnology and veterinary vaccines. The amino acid sequence of the multi-epitope fusion peptide is shown as SEQ ID NO: 1, the multi-epitope fusion peptide comprises dominant immune T cell and B cell antigen epitopes from a plurality of O-type and A-type foot-and-mouth disease virus epidemic strains, and a mycobacterium signal peptide is fused at the N terminal. The recombinant strain rBCG-MIPGA is successfully constructed by carrying out codon optimization on the fusion gene, cloning the fusion gene to a pMV306 vector and carrying out electrotransfection on BCG. The recombinant BCG can simultaneously excite high-titer specific antibodies aiming at foot-and-mouth disease virus type O and type A and remarkable T cell immune response, shows lasting and broad-spectrum protection potential, and has great application value in the aspect of preparing safe, efficient and broad-spectrum foot-and-mouth disease vaccines.

The invention discloses a Mycobacterium tuberculosis epitope mRNA (messenger Ribonucleic Acid) vaccine simulated, predicted and screened by a computer, which is prepared by the following steps: bacterial protein sequence acquisition and signal peptide analysis: acquiring amino acid sequences of proteins ESAT6, CFP10, Ag85A, Ag85B, TB10.4, PPE68, PPE18 and Rv1813c through a database; the method comprises the following steps: analyzing physicochemical properties of proteins, including the number of amino acids, the molecular weight, the instability index and the overall average value of water solubility, analyzing and predicting the allergy of the epitopes by using a server, and generating all potential mutants by using the server to predict and measure the toxicity of the epitopes; the multi-epitope mRNA vaccine candidate is successfully constructed by adopting computer simulation screening and optimization of the mycobacterium tuberculosis multi-epitope antigen, the vaccine design scheme is efficient, controllable and broad-spectrum, a theoretical basis and a candidate construct are provided for early research and development of tuberculosis vaccines, and the vaccine is expected to be used for prevention and control of tuberculosis and has positive influence on public health.

According to the invention, dominant antigen epitopes of main outer membrane proteins OspA, OspB and OspC of borrelia burgdorferi are screened out, and a multi-epitope fusion vaccine containing the epitopes and application are constructed. The vaccine design not only improves the specificity and immunogenicity of the antigen. Compared with a traditional antigen epitope screening and construction strategy, the method has the advantages that the cycle is shortened, the cost is reduced, meanwhile, the limitations of many and complex antigens, large toxic and side effects and the like of a traditional vaccine are overcome, the operation process is simplified, the method is more suitable for large-scale epitope screening, popularization and application, and a new thought and strategy are provided for research and development of borrelia burgdorferi vaccines.

The present disclosure provides compositions and methods related to multiparatopic aptamers. In particular, the present disclosure provides nucleic acid aptamers capable of binding multiple distinct epitopes on a target biomolecule, as well as corresponding methods of generating and characterizing the multiparatopic aptamers.

The invention belongs to the technical field of biology, and discloses a recombinant turkey herpesvirus, and a tandem epitope expression cassette is inserted between UL45 and UL46 of the recombinant turkey herpesvirus; the tandem epitope expression cassette is used for expressing a plurality of B cell epitopes and a plurality of T cell epitopes. According to the recombinant herpesvirus of turkeys, a tandem epitope is inserted into an HVT (herpesvirus of turkeys) vector, and experiments prove that the recombinant herpesvirus of turkeys can induce higher HI antibody and neutralizing antibody titer, obviously stimulate spleen T lymphocyte response of immunized chicken, and can generate an obvious challenge protection effect in 3 days; the challenge protection effect is obviously superior to that of a combined immunization scheme of H9N2 AIV multi-epitope recombinant baculovirus (BV-BNT) and InV provided by the applicant; meanwhile, the recombinant turkey herpesvirus is verified to be capable of performing intraembryonic vaccination and generating an obvious immune protection effect. Meanwhile, the invention further provides a preparation method and application of the recombinant turkey herpesvirus.

The invention belongs to the technical field of microbial immunity and DNA vaccines, and particularly relates to a preferred epitope peptide of a Crimean-Congo hemorrhagic fever virus envelope glycoprotein C terminal (CCHFV Gc), a tandem multi-epitope vaccine, an expression vector and application. The preferable epitope peptide is composed of any one amino acid sequence as shown in SEQ ID NO.1-SEQ ID NO.21, and the preferable epitope peptide has high affinity, strong immunogenicity and interspecific amp; and an intraspecific conservative preferred epitope. Preferably epitopes are connected in series through a linker to synthesize a series multi-epitope vaccine, the series multi-epitope vaccine enters cells to be expressed to form recombinant protein, then T lymphocytes are activated, and cellular immune response is induced. The in-vivo vaccine evaluation of animals is carried out by using the tandem multi-epitope vaccine, and it is proved that the vaccine can effectively induce anti-CCHFV specific cellular immune response and the application safety in BALB / c mice. The invention is helpful for understanding the immunobiology of CCHFV Gc and perfecting the epitope vaccine design for the virus in the future.

According to the echinococcus granulosus vaccine based on the self-assembly peptide, a peptide fragment, rich in dominant epitopes, in EgG1Y162-2 is connected to a Q11 amino terminal through '-SGSG-', due to the self-assembly effect of the Q11 peptide, the peptide fragment rich in dominant epitopes is repeatedly expressed on the surface of nanofibers, and therefore EgG1Y162 dominant multi-epitope self-assembly nano-polypeptide is formed; the EgG1Y162 dominant multi-epitope self-assembled nano polypeptide is adopted in the vaccine, so that the immune recognition and response of a body are effectively enhanced.

The invention discloses a gB, gH / gL and K8.1 multi-epitope DNA (deoxyribonucleic acid) vaccine for preventing KSHV (Kaposi's sarcoma associated herpes virus), and relates to the technical field of vaccines, in particular to a gB, gH / gL and K8.1 multi-epitope DNA vaccine for preventing KSHV infection, which is delivered by adopting a nano-carrier beta-CD-PEI, and simultaneously delivers a sulfo-modified small-fragment nucleic acid adjuvant, so that the KSHV infection can be effectively prevented and treated. The multi-epitope DNA vaccine mainly comprises four plasmids with His tags, the four plasmids are pcDNA3.1 (+)-gB-his, pcDNA3.1 (+)-K8.1-his, pcDNA3.1 (+)-gH-his and pcDNA3.1 (+)-gL-his, the four plasmids are combined on beta-CD-PEI through electrostatic adsorption, an adjuvant CPGodn1826 is adsorbed, and the KSHV nano multi-epitope DNA vaccine which is stable, high in delivery efficiency and good in immunogenicity is formed. The invention further provides a construction method of the DNA nano vaccine, the nano vaccine is characterized, and the immune effect is verified in a mouse body. Compared with a traditional vaccine, the vaccine provided by the invention has good immunogenicity and safety, and has a relatively great application prospect.

This invention relates to the field of biotechnology and provides an antigenic epitope of the parainfluenza virus type 5 F protein, a monoclonal antibody, and its applications. 135 AAILNLKNAIQKTNAAVADVVQA 157 Furthermore, a monoclonal antibody that specifically recognizes this antigenic epitope is provided. The amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown in SEQ ID NO.1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.2. The discovery of this epitope provides a new target for the development of PIV5 diagnostic reagents. Peptide antigens can be designed and synthesized based on this epitope to develop highly specific ELISA diagnostic kits. Simultaneously, this epitope can be used as a candidate epitope for the design of multi-epitope vaccines, providing a new strategy for the prevention and control of PIV5.

The invention relates to a construction method of a multi-epitope subunit vaccine of norovirus. The method comprises the following steps: determining a standardized construction principle and a design parameter system of the multi-epitope subunit vaccine by designing four different multi-epitope construction strategies; the method solves the ubiquitous problems of single construction mode, strong immunological enhancement dependence, insufficient antigen spectrum coverage and lack of a high-throughput screening system in the existing multi-epitope vaccine design, significantly shortens the vaccine design period, reduces the experiment cost, and improves the design accuracy. The multi-epitope subunit vaccine of the norovirus is obtained through the construction method, the amino acid sequence of the multi-epitope subunit vaccine is shown as any one of SEQ ID NO.3-5, and the strong immunogenicity and broad-spectrum protection potential of the multi-epitope subunit vaccine are verified through animal experiments.

The application discloses a multi-epitope fusion protein based on porcine rotavirus VP7 and VP8 double targets and a preparation method and application thereof. S.T As a skeleton, the advantages of precisely integrating VP7 and VP8 neutralizing epitopes are constructed into multi-epitope fusion antigen FliC S.T -VP7+VP8. The fusion protein has two immunological advantages: FliC S.T The skeleton has TLR5 adjuvant activity, can efficiently activate the innate immunity and adaptive immunity of a host, and can synchronously present key neutralizing epitopes of porcine rotavirus VP7 and VP8 through a multi-epitope strategy, so that high-titer specific neutralizing antibodies and strong cellular immune responses against the two structural proteins can be induced in the body. The application provides a multi-epitope fusion antigen of porcine rotavirus which integrates high immunogenicity and broad-spectrum neutralization protection, and provides a feasible technical scheme for the prevention and control of porcine rotavirus.

The invention belongs to the technical field of biological medicines, and particularly relates to a Brucella recombinant multi-epitope vaccine and application thereof. The invention provides a recombinant multi-epitope vaccine protein of Brucella. The vaccine protein is a first vaccine variant rBMEV1 or a second vaccine variant rBMEV2. Results of embodiments prove that the vaccine provided by the invention can excite strong cross immune response aiming at main pathogenic species (such as sheep species, cattle species and pig species) of Brucella. Animal experiments prove that the antibody can induce a high-level and lasting specific antibody, can obviously activate response of CD4 + and CD8 + T cells and corresponding cell factors, and has good safety at the same time. According to the invention, the problems of narrow protection spectrum, dependence on exogenous adjuvants, single immune type and the like of the traditional brucella vaccine are solved, and a new generation of efficient, broad-spectrum and safe candidate vaccine strategy is provided for prevention and control of brucellosis.

The invention provides a design method for improving the population coverage rate of a multi-epitope vaccine, which comprises the following steps: carrying out epitope prediction on B cells and T cells according to candidate proteins to obtain B cell epitopes and T cell epitopes; setting a sliding window for the candidate antigen protein; judging whether the needed epitope exists in the sliding window or not; if the needed epitope exists, shortening the length of the window by one amino acid, and judging whether the specifically bound MHC-I / II allele is reduced or not; if the MHC-1 / II allele is reduced, the window shortening operation is revoked, and overlapping epitopes which are specifically combined with the maximum MHC-1 / II allele are reserved, so that candidate overlapping epitopes are obtained. According to the invention, a three-type epitope maximization strategy based on a sliding window is adopted, and population coverage rate maximization and dual immune recognition are realized in a vaccine construct with a compact structure by recognizing the number of specific binding MHC-I / II alleles and the number of partially overlapped B cell epitope amino acids.

This invention discloses a recombinant BCG vaccine expressing a multi-epitope fusion peptide of foot-and-mouth disease virus (FMD) types O and A and its application, belonging to the fields of biotechnology and veterinary vaccines. The amino acid sequence of the multi-epitope fusion peptide is shown in SEQ ID NO:1, containing dominant immune T-cell and B-cell antigenic epitopes from multiple circulating FMD virus types O and A, and fused with a mycobacterial signal peptide at the N-terminus. This invention successfully constructed the recombinant strain rBCG-MIPGA by codon optimization of the fusion gene, cloning it into the pMV306 vector, and electroporating it into BCG. This recombinant BCG can simultaneously stimulate high-titer specific antibodies and significant T-cell immune responses against FMD virus types O and A, exhibiting durable and broad-spectrum protective potential, and has significant application value in the preparation of safe, efficient, and broad-spectrum FMD vaccines.

The invention discloses a bovine parainfluenza virus 3A and 3C type multi-epitope antigen peptide as well as a compound and application thereof. The amino acid sequences of the multi-epitope antigen peptides BPIV-3A and BPIV-3C are respectively shown as SEQ ID NO: 1 and SEQ ID NO: 3, and the multi-epitope antigen peptides are formed by connecting CTL epitopes, HTL epitopes and B cell epitopes screened from HN and F proteins of BPIV-3A and BPIV-3C strains. Animal immune tests show that the antigen peptide and the compound thereof can effectively stimulate a body to generate a specific IgG antibody and a neutralizing antibody, induce immune response of Th1 type cells, effectively eliminate viruses and relieve lung tissue lesions, and show good immunogenicity and protection effect. The invention provides an efficient and safe vaccine candidate for prevention and control of BPIV-3, and has a good application prospect.

This invention discloses a fusion multi-epitope antigen of the extracellular region of the rabies virus G protein and its application, belonging to the field of vaccines. This invention uses an insect cell-baculovirus expression system to express a recombinant fusion protein containing the extracellular region of the rabies virus G protein, the dendritic cell targeting peptide DCpep, and the universal T cell epitope PADRE, and displays it on the surface of bacterial-like particles via the peptidoglycan binding domain PA to obtain a recombinant subunit vaccine. Comparative experiments with this vaccine and commercial inactivated vaccines and adjuvanted recombinant subunit vaccines show that the recombinant subunit vaccine provided by this invention has good immunogenicity, can induce specific immune responses in mice and increase neutralizing antibody levels, achieves 100% protection in lethal rabies virus standard strain challenge experiments, significantly reduces viral load in the brain of infected mice, and provides effective challenge protection.

The invention belongs to the technical field of biology, and discloses a recombinant turkey herpesvirus, and a tandem epitope expression cassette is inserted between UL45 and UL46 of the recombinant turkey herpesvirus; the tandem epitope expression cassette is used for expressing a plurality of B cell epitopes and a plurality of T cell epitopes. According to the recombinant turkey herpesvirus, tandem epitopes are inserted into an HVT (turkey herpesvirus) carrier, and through experimental verification, good cellular immune response can be induced and generated in 1-day-old chicks and 18-day-old chick embryos by immunizing the multi-epitope recombinant HVT vaccine for one time, and compared with inactivated vaccines needing two-time immunization, the recombinant turkey herpesvirus can provide earlier and better challenge protection effect. Meanwhile, the recombinant turkey herpesvirus is verified to be capable of performing intraembryonic vaccination and generating an obvious immune protection effect. Meanwhile, the invention further provides a preparation method and application of the recombinant turkey herpesvirus.

The present application belongs to the technical field of genetic engineering, and particularly relates to a bovine rotavirus group A multi-epitope fusion protein and application thereof. The present application provides a bovine rotavirus group A multi-epitope peptide, fusion protein based on ferritin nanocarriers and application thereof. The multi-epitope peptide is based on bovine rotavirus group A VP4 and VP7 protein sequences, and highly conserved and strong immunogenicity cytotoxic T lymphocyte epitopes, helper T cell epitopes and B cell epitopes are screened by using immunoinformatics technology, and are spliced to form a multi-epitope fusion antigen with good conformational stability. Immunological evaluation shows that the multi-epitope fusion antigen has good antigen specificity and neutralizing activity. Animal experiment results show that the epitope peptide and fusion protein can induce the body to produce high-level neutralizing antibodies against multiple genotypes of BRVA G6, G8 and G10, and significantly improve the broad spectrum and durability of immunoprotection.

The invention discloses an African swine fever virus multi-epitope virus-like particle containing a phage AP205 dimer structure as well as a preparation method and application of the African swine fever virus multi-epitope virus-like particle. The multi-epitope virus-like particle of the African swine fever virus is obtained by taking a dimer of a phage AP205 as a skeleton, displaying a multi-epitope sequence of the African swine fever virus on the surface of the dimer of the phage AP205 by utilizing a thallus display technology and then carrying out in-vitro self-assembly, the dimer of the bacteriophage AP205 is obtained by connecting two bacteriophage AP205 sequences in series through a linker. The designed AP205 dimer structure can successfully display antigen epitopes, has a typical VLP structural form, and compared with an AP205 monomer, the AP205 dimer structure can improve the assembly efficiency of multi-epitope VLP and can induce strong immune response, which fully shows that the antigen immunogenicity and immune response ability are enhanced by using the AP205 dimer structure, and the immunogenicity of the antigen is improved. The method is a VLP vaccine design strategy with a very good application prospect, and has very important significance on prevention and control of African swine fever and research and development of safe and effective veterinary vaccines.

The application belongs to the technical field of biotechnology, and provides a Streptococcus suis type 2 (SS2) multi-epitope inhalation subunit vaccine and application thereof.Four CTL epitopes, seven HTL epitopes and six B cell epitopes are screened from the conserved epitopes of SS2 virulence factors SSU05-1022 and SpaA, and the four CTL epitopes, the seven HTL epitopes and the six B cell epitopes are fused by AAY / GPGPG / EAAAK linkers and introduced into L7 / L12 ribosomal protein as an adjuvant to construct an inhalation subunit vaccine 1022-SpaA V3.The vaccine is intranasally primed and boosted at 60 μg, can improve respiratory mucosa sIgA and serum IgG levels, activate related immune cells, and form a mucosal and systemic double immune mechanism.The survival rate of mice after SS2 multi-strain challenge is up to 100%, and the bacterial load can be reduced.The vaccine is safe and non-toxic, inhalation can save cost, and is suitable for industrial scale production.